Holen Sie sich die Stockscreener-App
3.14
1.95%
0.06
Handel nachbörslich:
3.11
-0.03
-0.96%
Schlusskurs vom Vortag:
$3.08
Offen:
$3.09
24-Stunden-Volumen:
2.46M
Relative Volume:
1.93
Marktkapitalisierung:
$340.20M
Einnahmen:
$27.08M
Nettoeinkommen (Verlust:
$-37.00M
KGV:
-6.0385
EPS:
-0.52
Netto-Cashflow:
$-18.46M
1W Leistung:
-3.38%
1M Leistung:
+27.64%
6M Leistung:
+121.13%
1J Leistung:
+13.36%
1-Tages-Spanne:
$3.05
$3.23
1-Wochen-Bereich:
$3.03
$3.385
52-Wochen-Spanne:
$1.05
$3.475
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Firmenname
Aclaris Therapeutics Inc
Sektor
Branche
Telefon
484-324-7933
Adresse
701 LEE ROAD, WAYNE, PA
Vergleichen Sie ACRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
3.14 | 333.70M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-05-28 | Eingeleitet | Wedbush | Outperform |
| 2025-03-18 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2024-12-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Hochstufung | BTIG Research | Neutral → Buy |
| 2024-11-19 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-19 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Eingeleitet | Evercore ISI | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2022-10-06 | Eingeleitet | BTIG Research | Buy |
| 2021-07-23 | Fortgesetzt | Jefferies | Buy |
| 2021-06-15 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-10-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Eingeleitet | SVB Leerink | Outperform |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2018-02-09 | Eingeleitet | Guggenheim | Buy |
| 2017-06-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Eingeleitet | Leerink Partners | Outperform |
| 2016-09-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-06-10 | Eingeleitet | Guggenheim | Buy |
| 2015-11-02 | Eingeleitet | Citigroup | Buy |
| 2015-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Is Aclaris Therapeutics Inc. (8AT) stock good for wealth creationWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - ulpravda.ru
Will Aclaris Therapeutics Inc. stock deliver strong dividend growthJuly 2025 Breakouts & Risk Managed Investment Strategies - ulpravda.ru
Why Aclaris Therapeutics Inc. stock could see breakout soonJuly 2025 Sector Moves & Safe Capital Growth Tips - ulpravda.ru
Why Aclaris Therapeutics Inc. stock could rally in 2025July 2025 Patterns & Expert Approved Momentum Ideas - ulpravda.ru
Why Aclaris Therapeutics Inc. stock is rated strong buyJuly 2025 Gainers & Free Community Consensus Stock Picks - ulpravda.ru
How analysts rate Aclaris Therapeutics Inc. stock todayJuly 2025 Catalysts & Safe Capital Preservation Plans - ulpravda.ru
Layoff Watch: Why Aclaris Therapeutics Inc. stock could rally in 2025 - ulpravda.ru
Aclaris Therapeutics Begins Phase 1a/1b Trial for Investigational Bispecific Antibody ATI-052 - MSN
Aclaris Therapeutics Included in Nasdaq Biotechnology Index - marketscreener.com
Aclaris Therapeutics Added to Nasdaq Biotechnology Index Effective December 19, 2025 - Quiver Quantitative
Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) - The Manila Times
Is Aclaris Therapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Weekly Top Stock Performers List - ulpravda.ru
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) 25% Share Price Surge Not Quite Adding Up - simplywall.st
Aclaris Therapeutics (NASDAQ:ACRS) Nasdaq Top 100 Biotech Model - Kalkine Media
Why Aclaris Therapeutics Inc. stock remains undervaluedWeekly Trading Summary & Real-Time Buy Zone Alerts - Bollywood Helpline
Can Upcoming ATI-2138 And Bosakitug Data Drive Momentum For Aclaris Therapeutics In 2026? - RTTNews
Aclaris Therapeutics Earnings Notes - Trefis
Aclaris Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - setenews.com
Can Aclaris Therapeutics Inc. stock deliver sustainable ROE2025 Key Highlights & Consistent Return Investment Signals - Newser
Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerTrade Risk Assessment & Weekly Stock Performance Updates - Newser
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
How Aclaris Therapeutics Inc. (8AT) stock correlates with oil markets2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser
Can Comfort Intech Limited Maintain Profitability in a Rising Rate EnvironmentCandlestick Trading Patterns & Free Dynamic Profit Opportunities - earlytimes.in
Is Aclaris Therapeutics Inc. stock attractive for income investors2025 Big Picture & Safe Capital Growth Trade Ideas - Newser
Aclaris Therapeutics (ACRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Aclaris Therapeutics engages investors at Piper Sandler Conference - Traders Union
Aclaris Therapeutics Inc (ACRS) is looking forward to a strong quarter - Setenews
Can Aclaris Therapeutics Inc. stock beat analyst upgradesJuly 2025 Gainers & Free Community Consensus Stock Picks - moha.gov.vn
Check out Aclaris Therapeutics's stock price (ACRS) in real time - CNBC
Aclaris Therapeutics, Inc.Common Stock (NQ: ACRS - Markets Financial Content
Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Top investors say Aclaris Therapeutics Inc (ACRS) ticks everything they need - setenews.com
Why Aclaris Therapeutics Inc. (8AT) stock attracts HNW investors - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock bottoming after sell offMarket Risk Analysis & Growth Focused Entry Reports - newser.com
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Discovering Aclaris Therapeutics And Two Other Noteworthy Penny Stocks - Yahoo Finance
How Aclaris Therapeutics Inc. stock benefits from tech adoptionNew Guidance & Smart Money Movement Alerts - newser.com
What hedge fund moves indicate for Aclaris Therapeutics Inc. (8AT) stockTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Is Aclaris Therapeutics Inc. stock a contrarian buyPortfolio Performance Report & Entry Point Confirmation Signals - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock benefit from mergers2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock a buy for dividend portfoliosLayoff News & Fast Momentum Entry Tips - newser.com
How cyclical is Aclaris Therapeutics Inc. (8AT) stock compared to rivalsPortfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Finanzdaten der Aclaris Therapeutics Inc-Aktie (ACRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):